Alcázar Jackson J, Campodónico Paola R, López René
Centro de Química Médica, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago 7780272, Chile.
Departamento de Paciente Crítico, Clínica Alemana de Santiago, Santiago 7650568, Chile.
Molecules. 2025 Aug 18;30(16):3401. doi: 10.3390/molecules30163401.
The escalating crisis of multidrug resistance, together with the persistence of antibiotic residues in clinical and environmental matrices, demands integrated strategies that couple sensitive detection, efficient decontamination, and controlled delivery. However, current techniques for quantifying avibactam (AVI)-a broad-spectrum β-lactamase inhibitor-such as HPLC-UV lack the sensitivity and specificity required for both therapeutic drug monitoring and environmental surveillance. Encapsulation of AVI within cyclodextrins (CDs) may simultaneously enhance its stability, bioavailability, and detectability, while the high binding affinities of CDs position them as molecular traps capable of scavenging residual AVI. In this study, the inclusion complexation of AVI with various CDs was examined through molecular dynamics (MD) simulations, experimental isothermal titration calorimetry (ITC), and non-covalent interaction (NCI) analysis. Stable 1:1 inclusion complexes were observed between AVI and β-cyclodextrin (β-CD), 2,6-dimethyl-β-cyclodextrin (DM-β-CD), and 2-hydroxypropyl-β-cyclodextrin (HP-β-CD), with standard Gibbs free energies of binding (ΔG°) of -3.64, -3.24, and -3.11 kcal/mol, respectively. In contrast, γ-cyclodextrin (γ-CD) exhibited significantly weaker binding (ΔG° = -2.25 kcal/mol). DFT-based NCI analysis revealed that cooperative interaction topology and cavity complementarity, rather than the sheer number of localized contacts, govern complex stability. Combined computational and experimental data establish β-CD derivatives as effective supramolecular hosts for AVI, despite an entropic penalty in the DM-β-CD/AVI complex. These CD-AVI affinities support the development of improved analytical methodologies and pharmaceutical formulations, and they also open avenues for decontamination strategies based on molecular trapping of AVI.
多重耐药性危机不断升级,加之临床和环境基质中抗生素残留持续存在,这就需要采取综合策略,将灵敏检测、高效去污和精准递送结合起来。然而,目前用于定量检测广谱β-内酰胺酶抑制剂阿维巴坦(AVI)的技术,如高效液相色谱-紫外检测法(HPLC-UV),缺乏治疗药物监测和环境监测所需的灵敏度和特异性。将AVI包封在环糊精(CDs)中可能会同时提高其稳定性、生物利用度和可检测性,而CDs的高结合亲和力使其成为能够清除残留AVI的分子陷阱。在本研究中,通过分子动力学(MD)模拟、实验等温滴定量热法(ITC)和非共价相互作用(NCI)分析,研究了AVI与各种CDs的包合络合作用。在AVI与β-环糊精(β-CD)、2,6-二甲基-β-环糊精(DM-β-CD)和2-羟丙基-β-环糊精(HP-β-CD)之间观察到稳定的1:1包合络合物,其结合的标准吉布斯自由能(ΔG°)分别为-3.64、-3.24和-3.11 kcal/mol。相比之下,γ-环糊精(γ-CD)的结合力明显较弱(ΔG° = -2.25 kcal/mol)。基于密度泛函理论(DFT)的NCI分析表明,协同相互作用拓扑结构和空腔互补性,而非局部接触的数量,决定了络合物的稳定性。尽管DM-β-CD/AVI络合物存在熵罚,但计算和实验数据相结合表明,β-CD衍生物是AVI有效的超分子主体。这些CD-AVI亲和力有助于开发改进的分析方法和药物制剂,也为基于AVI分子捕获的去污策略开辟了道路。